Posted On: 08/04/2015 11:10:07 PM
Post# of 30066
There is a whole lot of Alzheimer's testing needed...
http://www.alz.org/research/clinical_trials/w...trials.asp
Dr. Jeffrey Commings, member of Amarantus's Alzheimer's Disease Diagnostics SAB, is interviewed on Biogen's Aducanumab. The company is currently enrolling patients for an upcoming large scale (2700 participants) 18-month Phase 3 trial.
https://www.youtube.com/watch?v=NVzNBqIevRI
Other trials among the 130 include as example:
Eli Lilly’s solanezumab, is currently running a large phase III trial, slated to end in October 2016, only in people with mild Alzheimer’s disease. Lilly's previous study didn't actually measure amyloid decline.
Axovant anticipates starting a phase 3 trial by the fourth quarter of this year and could bring RVT-101 to pharmacy shelves by as early as 2017
Roche's anti-amyloid plaque monoclonal antibody crenezumab will move into late-stage Phase 3 development. The company is looking to begin new clinical trials of its other monoclonal antibody, ganternerumab, after shutting down a Phase 3 trial in December.
Dr. JEFFREY L. CUMMINGS, M.D., SC.D.
http://www.amarantus.com/about/alzheimers-dis...ostics-sab
Quote:
Today, at least 50,000 volunteers, both with and without Alzheimer's disease, are urgently needed to participate in more than 130 actively enrolling clinical trials about Alzheimer's and related dementias.
http://www.alz.org/research/clinical_trials/w...trials.asp
Dr. Jeffrey Commings, member of Amarantus's Alzheimer's Disease Diagnostics SAB, is interviewed on Biogen's Aducanumab. The company is currently enrolling patients for an upcoming large scale (2700 participants) 18-month Phase 3 trial.
https://www.youtube.com/watch?v=NVzNBqIevRI
Other trials among the 130 include as example:
Eli Lilly’s solanezumab, is currently running a large phase III trial, slated to end in October 2016, only in people with mild Alzheimer’s disease. Lilly's previous study didn't actually measure amyloid decline.
Axovant anticipates starting a phase 3 trial by the fourth quarter of this year and could bring RVT-101 to pharmacy shelves by as early as 2017
Roche's anti-amyloid plaque monoclonal antibody crenezumab will move into late-stage Phase 3 development. The company is looking to begin new clinical trials of its other monoclonal antibody, ganternerumab, after shutting down a Phase 3 trial in December.
Dr. JEFFREY L. CUMMINGS, M.D., SC.D.
http://www.amarantus.com/about/alzheimers-dis...ostics-sab
(0)
(0)
